Roche to present results of first prospective trial using blood-based next generation sequencing which successfully identifies people for treatment with Alecensa
September 30, 2019 02:30 ET
|
F. Hoffmann-La Roche Ltd
Efficacy of Alecensa® (alectinib) in people identified to have ALK-positive non-small cell lung cancer using liquid biopsy is consistent with efficacy in those identified by tissue analysis in the...
FDA approves Roche’s Rituxan (rituximab) in children with two rare blood vessel disorders
September 30, 2019 01:05 ET
|
F. Hoffmann-La Roche Ltd
Rituxan is the first and only FDA-approved treatment for paediatric patients 2 years of age and older living with granulomatosis with polyangiitis or microscopic polyangiitisThese two forms of...
Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.
September 30, 2019 01:00 ET
|
F. Hoffmann-La Roche Ltd
Basel, 30 September 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that Roche has extended the offering period of its previously...
Roche to present new and updated data at ESMO 2019 reinforcing the use of Alecensa in the first-line setting for advanced ALK-positive non-small cell lung cancer
September 28, 2019 01:00 ET
|
F. Hoffmann-La Roche Ltd
New real-world data from the Flatiron database supports clinical benefits of Alecensa® (alectinib) across time to treatment discontinuation, real-world progression free survival and overall survival...
Roche's Tecentriq improves overall survival as a first-line monotherapy in certain people with advanced non-small cell lung cancer
September 27, 2019 10:00 ET
|
F. Hoffmann-La Roche Ltd
Phase III IMpower110 study showed Tecentriq monotherapy helped people with advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression live longer compared with chemotherapy aloneData will...
Roche’s Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma
September 27, 2019 08:00 ET
|
F. Hoffmann-La Roche Ltd
The study showed a confirmed objective response rate of 36% for people treated with the Tecentriq and Avastin combination in unresectable hepatocellular carcinoma who have not received prior systemic...
Roche to present new data from its broad oncology portfolio at the European Society for Medical Oncology 2019 Congress
September 23, 2019 01:00 ET
|
F. Hoffmann-La Roche Ltd
First positive results from a Phase III cancer immunotherapy combination study in people with previously untreated advanced bladder cancerFirst results from the BFAST study testing Foundation...
FDA approves cobas Babesia, Roche’s first whole blood test for donor screening
September 20, 2019 01:00 ET
|
F. Hoffmann-La Roche Ltd
Roche is dedicated to helping save patients’ lives by delivering state-of-the-art solutions to aid in the protection of the global blood supply from infectious diseasesIf undetected, Babesia infection...
Roche renouvelle son engagement en faveur des trains médicaux Phelophepa, marquant leur 25e anniversaire
September 19, 2019 01:00 ET
|
F. Hoffmann-La Roche Ltd
Roche et Transnet, principale entreprise sud-africaine de logistique de fret, se sont associées en 1994 pour créer Phelophepa, premier établissement de soins de santé primaires complets sur rails au...
Roche renews its commitment to the primary healthcare Phelophepa trains, marking the 25th anniversary
September 19, 2019 01:00 ET
|
F. Hoffmann-La Roche Ltd
Roche and Transnet, the main freight logistics company in South Africa, came together in 1994 to establish Phelophepa, the world’s first comprehensive primary healthcare facility on railPhelophepa has...